Evidence map›Paper›PMID 38728394›Full record

ArticleScience advances2024

CD8

Ravi F Iyer, Marieke C Verweij, Sujit S Nair, David Morrow, Mandana Mansouri, Dimple Chakravarty, Teresa Beechwood, Christine Meyer, Luke Uebelhoer, Elvin J Lauron and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. The CD94/NKG2A-HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  4. Article
  5. Article
  6. Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Review
  7. Review
  8. Review
  9. The murine MHC-E molecule Qa-1Frontiers in immunology · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ravi F IyerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-2249-266X
Marieke C VerweijVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-6556-8682
Sujit S NairDepartment of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA.ORCID 0000-0002-3039-523X
David MorrowVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-4686-830X
Mandana MansouriVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-1299-0817
Dimple ChakravartyDepartment of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA.ORCID 0000-0002-5021-4440
Teresa BeechwoodVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0009-0008-8493-6071
Christine MeyerVir Biotechnology, San Francisco, CA 14158, USA.ORCID 0009-0006-7683-9664
Luke UebelhoerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
Elvin J LauronVir Biotechnology, San Francisco, CA 14158, USA.
Andrea SelsethVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-9536-463X
Nessy JohnVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-4114-4946
Tin Htwe ThinDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-7891-1459
Siarhei DzedzikDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Colin Havenar-DaughtonVir Biotechnology, San Francisco, CA 14158, USA.ORCID 0000-0002-2880-3927
Michael K AxthelmVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-1984-5906
Janet DouglasVir Biotechnology, San Francisco, CA 14158, USA.
Alan KormanVir Biotechnology, San Francisco, CA 14158, USA.ORCID 0000-0002-1142-8542
Nina BhardwajDepartment of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA.ORCID 0000-0003-1865-4187
Ashutosh K TewariDepartment of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA.ORCID 0000-0002-3146-4524
Scott HansenVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-9845-6481
Daniel MalouliVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-1287-7283
Louis J PickerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-0546-398X
Klaus FrühVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-8014-3877

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Virology and Immunology MonitoringP01AI094417 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2011 to 2016
$20.5M
Role of Memory T Cell Dynamics in SIV InfectionR37AI054292 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2008 to 2017
$9.8M
Evasion of Antigen Presentation by Rhesus CytomegalovirusR01AI059457 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI FRUH, KLAUS J · 2005 to 2021
$6.2M
Development and In Vivo Characterization of Safety-Enhanced RhCMV/SIV VectorsR01AI095113 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2011 to 2015
$4.1M
NIAID NIH HHS P01 AI094417NIAID NIH HHS R01 AI059457NIAID NIH HHS R01 AI095113NIAID NIH HHS R37 AI054292NIH HHS P51 OD011092
6 · The paper itself

Abstract

The nonpolymorphic major histocompatibility complex E (MHC-E) molecule is up-regulated on many cancer cells, thus contributing to immune evasion by engaging inhibitory NKG2A/CD94 receptors on NK cells and tumor-infiltrating T cells. To investigate whether MHC-E expression by cancer cells can be targeted for MHC-E-restricted T cell control, we immunized rhesus macaques (RM) with rhesus cytomegalovirus (RhCMV) vectors genetically programmed to elicit MHC-E-restricted CD8

Indexed as

Antigens, NeoplasmCD8-Positive T-LymphocytesHLA-E AntigensAcid PhosphataseAnimalsAntigen PresentationCancer VaccinesCell Line, TumorCytomegalovirusHistocompatibility Antigens Class IHumansMacaca mulattaMaleMesothelinAcid PhosphataseAntigens, NeoplasmCancer VaccinesHistocompatibility Antigens Class IHLA-E AntigensMesothelinprostatic acid phosphatase

Identifiers

PMID38728394
PMCPMC11086602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.